Latest filings (excl ownership)
8-K
Regulation FD Disclosure
19 Dec 24
8-K
Departure of Directors or Certain Officers
4 Dec 24
8-K
Entry into a Material Definitive Agreement
15 Nov 24
10-Q
2024 Q3
Quarterly report
13 Nov 24
8-K
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
13 Nov 24
8-K
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia
12 Nov 24
8-K
Departure of Directors or Certain Officers
3 Oct 24
8-K
Departure of Directors or Certain Officers
26 Sep 24
8-K
Regulation FD Disclosure
26 Aug 24
8-K
Departure of Directors or Certain Officers
15 Aug 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
8-K
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
13 Aug 24
8-K
Departure of Directors or Certain Officers
25 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
22 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
21 Mar 24
8-K
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
4 Mar 24
S-8
Registration of securities for employees
23 Jan 24
S-8
Registration of securities for employees
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
14 Nov 23
UPLOAD
Letter from SEC
13 Nov 23
CORRESP
Correspondence with SEC
7 Nov 23
UPLOAD
Letter from SEC
26 Oct 23
8-K
Departure of Directors or Certain Officers
20 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
14 Aug 23
ARS
2022 FY
Annual report to shareholders
3 Aug 23
DEFA14A
Additional proxy soliciting materials
3 Aug 23
DEF 14A
Definitive proxy
3 Aug 23
PRE 14A
Preliminary proxy
24 Jul 23
8-K
Departure of Directors or Certain Officers
19 Jul 23
8-K
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
11 Jul 23
8-K
Results of Operations and Financial Condition
27 Jun 23
8-K
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update
11 May 23
Latest ownership filings
4
Kostas D Odysseas
7 Feb 25
4
Sarah J. Schlesinger
7 Feb 25
4
Todd C. Peterson
7 Feb 25
4
JOSEPH M PATTI
7 Feb 25
4
Pierre Kyme
7 Feb 25
4
Robin Kramer
7 Feb 25
4
David Duane House
7 Feb 25
4
Jules Haimovitz
7 Feb 25
4
Deborah Birx
7 Feb 25
SC 13D/A
Innoviva, Inc.
14 Nov 24
4
David Duane House
3 Oct 24
3
David Duane House
19 Aug 24
3
Pierre Kyme
28 Jun 24
4
JOSEPH M PATTI
18 Mar 24
4
Robin Kramer
18 Mar 24
4
Todd C. Peterson
18 Mar 24
4
Richard Rychlik
18 Mar 24
4
Sarah J. Schlesinger
18 Mar 24
4
Jules Haimovitz
18 Mar 24
4
Kostas D Odysseas
18 Mar 24
4
Deborah Birx
18 Mar 24
SC 13D/A
Innoviva, Inc.
4 Mar 24
4
Sarah J. Schlesinger
26 Dec 23
4
Todd C. Peterson
26 Dec 23
4
Robin Kramer
26 Dec 23
4
JOSEPH M PATTI
26 Dec 23
4
Richard Rychlik
26 Dec 23
4
Jules Haimovitz
26 Dec 23
4
Deborah Birx
26 Dec 23
4
Kostas D Odysseas
26 Dec 23
3
Richard Rychlik
22 Sep 23
3
Deborah Birx
19 Jul 23
SC 13D/A
Innoviva, Inc.
11 Jul 23
3
Julianne Averill
8 May 23
3
Erin Butler
7 Feb 23
4
Change in insider ownership
12 Jan 23
SC 13D/A
Innoviva, Inc.
10 Jan 23
4
Todd C. Peterson
15 Apr 22
4
Todd Patrick
15 Apr 22
4
Sarah J. Schlesinger
15 Apr 22